Please provide your email address to receive an email when new articles are posted on . Olaparib reduced risk for invasive and distant DFS compared with placebo. A lower percentage patients who ...

Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.

These findings were published as a supplement in Annals of Oncology and presented during the 2023 ESMO Congress. 1 They showed that chemotherapy among 187 patients resulted in a median OS of 32.7 ...

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial ...

Treatment arms (SOC [once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin], cediranib, olaparib, or cediranib/olaparib) were equally randomized. A preplanned interim futility analysis ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations ...

SAN ANTONIO — Nearly 10 years along patients with high-risk BRCA-positive breast cancers who had been treated with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza ...

At six years, 79.6% of olaparib-treated patients remained free of invasive recurrence and 83.5% remained free of distant recurrence, compared to 70.3% and 75.7%, respectively, in the placebo group.

Olaparib monotherapy demonstrates clinical benefit despite use in later lines of therapy in a real-world study of patients with mCRPC and human recombinant repair gene mutations. Several lines of ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2 ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2 ...